骨代谢生化指标对前列腺癌骨转移的诊断价值(2)
http://www.100md.com
2010年8月1日
 |
| 第1页 |
参见附件(1651KB，2页)。
参考文献
[1]Kuwahara M,Tochigi4T,Kawamura S,et al.Mass screening for prostate cancer:a comparative study in Natori,Japan and changchun,china[J].Urology,2003,61(1):137.
[2]Kiuchi K,Ishikawa T,Hamaguchi Y,et al.Cross-linked collagen C-and N-telopeptides for an early diagnosis of bone metastasis from breast cancer.Oncol Rep,2002,9(3):595-598.
[3]Izumi M,Nakanishi Y,Takayama K,et al.Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma.Cancer,2001 Apr 15,91(8):1487-1493.
[4]Birtle AJ,Freeman A,Masters JR,et al.Clinical features of patients who present with mestastatic prostate carcinoma and serum prostate specific antigen (PSA) lever<10ug/l:the ”PSA negative”patients [J].Cancer,2003,98(11):2362.
[5]邸立军,刘淑俊,宛凤玲,等.尿吡啶酚和脱氧吡啶酚在恶性肿瘤骨转移中的临床意义[J].中国肿瘤临床,2000,7(27):521-522.
[6]Izumi M,Nakanishi Y,Takayama K,et al.Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma[J].Cancer,2001,91(8):1487-1493.
[7]Horiguchi T,Tachikawa S,Kondo R,et al.Usefulness of serum carboxy-terminal telopeptide of type I collagen(ICTP)as a marker of bone metastasis from lung cancer[J].Jpn J Clin Oncol,2000,30(4):174-179.
您现在查看是摘要介绍页，详见PDF附件(1651KB，2页)。